Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther June 1 2011 10 (6) 915-915;

Therapeutic Discovery

  • Therapeutic Discovery | Free Article
    Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance
    Milos Dokmanovic, Yi Shen, Tabetha M. Bonacci, Dianne S. Hirsch and Wen Jin Wu
    Mol Cancer Ther June 1 2011 10 (6) 917-928; DOI:10.1158/1535-7163.MCT-10-0980

  • Therapeutic Discovery
    Overexpression of Mitotic Centromere–Associated Kinesin Stimulates Microtubule Detachment and Confers Resistance to Paclitaxel
    Anutosh Ganguly, Hailing Yang and Fernando Cabral
    Mol Cancer Ther June 1 2011 10 (6) 929-937; DOI:10.1158/1535-7163.MCT-10-1109

  • Therapeutic Discovery
    Cancer Cells Cyclically Lose and Regain Drug-Resistant Highly Tumorigenic Features Characteristic of a Cancer Stem-like Phenotype
    Kaijie He, Tong Xu and Amir Goldkorn
    Mol Cancer Ther June 1 2011 10 (6) 938-948; DOI:10.1158/1535-7163.MCT-10-1120

  • Therapeutic Discovery
    The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
    Jenny E. Hernandez-Davies, Joan P. Zape, Elliot M. Landaw, Xiaolin Tan, Ajia Presnell, Diana Griffith, Michael C. Heinrich, Keith B. Glaser and Kathleen M. Sakamoto
    Mol Cancer Ther June 1 2011 10 (6) 949-959; DOI:10.1158/1535-7163.MCT-10-0904

  • Therapeutic Discovery
    B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
    Hao Liu, Christina Tekle, Yih-Wen Chen, Alexandr Kristian, Yuhua Zhao, Ming Zhou, Zixing Liu, Yan Ding, Bin Wang, Gunhild Mari Mælandsmo, Jahn Marthin Nesland, Oystein Fodstad and Ming Tan
    Mol Cancer Ther June 1 2011 10 (6) 960-971; DOI:10.1158/1535-7163.MCT-11-0072

  • Therapeutic Discovery | Free Article
    Targeted Nanogels: A Versatile Platform for Drug Delivery to Tumors
    Eric A. Murphy, Bharat K. Majeti, Rajesh Mukthavaram, Lisette M. Acevedo, Leo A. Barnes and David A. Cheresh
    Mol Cancer Ther June 1 2011 10 (6) 972-982; DOI:10.1158/1535-7163.MCT-10-0729

  • Therapeutic Discovery
    Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3
    Tom Van Maerken, Ali Rihani, Daniel Dreidax, Sarah De Clercq, Nurten Yigit, Jean-Christophe Marine, Frank Westermann, Anne De Paepe, Jo Vandesompele and Frank Speleman
    Mol Cancer Ther June 1 2011 10 (6) 983-993; DOI:10.1158/1535-7163.MCT-10-1090

  • Therapeutic Discovery
    A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B–Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos
    Laura L. Vollmer, Maria Jiménez, Daniel P. Camarco, Wei Zhu, Hikmat N. Daghestani, Raghavan Balachandran, Celeste E. Reese, John S. Lazo, Neil A. Hukriede, Dennis P. Curran, Billy W. Day and Andreas Vogt
    Mol Cancer Ther June 1 2011 10 (6) 994-1006; DOI:10.1158/1535-7163.MCT-10-1048

Preclinical Development

  • Preclinical Development
    Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
    Anne-Christine Piguet, Bettina Saar, Ruslan Hlushchuk, Marie V. St-Pierre, Paul M.J. McSheehy, Vesna Radojevic, Maresa Afthinos, Luigi Terracciano, Valentin Djonov and Jean-François Dufour
    Mol Cancer Ther June 1 2011 10 (6) 1007-1017; DOI:10.1158/1535-7163.MCT-10-0666

  • Preclinical Development | Free Article
    The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
    Wei Fu, Le Ma, Baoky Chu, Xue Wang, Marilyn M. Bui, Jennifer Gemmer, Soner Altiok and W. Jackson Pledger
    Mol Cancer Ther June 1 2011 10 (6) 1018-1027; DOI:10.1158/1535-7163.MCT-11-0167

  • Preclinical Development
    Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
    Joseph M. Gozgit, Matthew J. Wong, Scott Wardwell, Jeffrey W. Tyner, Marc M. Loriaux, Qurish K. Mohemmad, Narayana I. Narasimhan, William C. Shakespeare, Frank Wang, Brian J. Druker, Tim Clackson and Victor M. Rivera
    Mol Cancer Ther June 1 2011 10 (6) 1028-1035; DOI:10.1158/1535-7163.MCT-10-1044

  • Preclinical Development
    Induction of In Vitro and In Vivo NK Cell Cytotoxicity Using High-Avidity Immunoligands Targeting Prostate-Specific Membrane Antigen in Prostate Carcinoma
    Ron D. Jachimowicz, Giulio Fracasso, Paul J. Yazaki, Barbara E. Power, Peter Borchmann, Andreas Engert, Hinrich P. Hansen, Katrin S. Reiners, Madlener Marie, Elke Pogge von Strandmann and Achim Rothe
    Mol Cancer Ther June 1 2011 10 (6) 1036-1045; DOI:10.1158/1535-7163.MCT-10-1093

  • Preclinical Development
    ATM and p53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance
    Julie Millour, Natalia de Olano, Yoshiya Horimoto, Lara J. Monteiro, Julia K. Langer, Rosa Aligue, Nabil Hajji and Eric W.-F. Lam
    Mol Cancer Ther June 1 2011 10 (6) 1046-1058; DOI:10.1158/1535-7163.MCT-11-0024

  • Preclinical Development
    Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
    Victor M. Rivera, Rachel M. Squillace, David Miller, Lori Berk, Scott D. Wardwell, Yaoyu Ning, Roy Pollock, Narayana I. Narasimhan, John D. Iuliucci, Frank Wang and Tim Clackson
    Mol Cancer Ther June 1 2011 10 (6) 1059-1071; DOI:10.1158/1535-7163.MCT-10-0792

  • Preclinical Development
    Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
    Robert M. Sharkey, Habibe Karacay, Serengulam V. Govindan and David M. Goldenberg
    Mol Cancer Ther June 1 2011 10 (6) 1072-1081; DOI:10.1158/1535-7163.MCT-11-0115

  • Preclinical Development
    Effective Melanoma Immunotherapy with Interleukin-2 Delivered by a Novel Polymeric Nanoparticle
    Hong Yao, Samuel S. Ng, Long-Fei Huo, Billy K. C. Chow, Zan Shen, Min Yang, Johnny Sze, Otis Ko, Ming Li, Alexander Yue, Li-Wei Lu, Xiu-Wu Bian, Hsiang-Fu Kung and Marie C. Lin
    Mol Cancer Ther June 1 2011 10 (6) 1082-1092; DOI:10.1158/1535-7163.MCT-10-0717

Molecular Medicine in Practice

  • Molecular Medicine in Practice | Free Article
    PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
    Ana M. Gonzalez-Angulo, Jaime Ferrer-Lozano, Katherine Stemke-Hale, Aysegul Sahin, Shuying Liu, Juan A. Barrera, Octavio Burgues, Ana M. Lluch, Huiqin Chen, Gabriel N. Hortobagyi, Gordon B. Mills and Funda Meric-Bernstam
    Mol Cancer Ther June 1 2011 10 (6) 1093-1101; DOI:10.1158/1535-7163.MCT-10-1089

  • Molecular Medicine in Practice
    Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
    Monika E. Hegi, Annie-Claire Diserens, Pierre Bady, Yuta Kamoshima, Mathilde C. M. Kouwenhoven, Mauro Delorenzi, Wanyu L. Lambiv, Marie-France Hamou, Matthias S. Matter, Arend Koch, Frank L. Heppner, Yasuhiro Yonekawa, Adrian Merlo, Karl Frei, Luigi Mariani and Silvia Hofer
    Mol Cancer Ther June 1 2011 10 (6) 1102-1112; DOI:10.1158/1535-7163.MCT-11-0048

  • Molecular Medicine in Practice
    Hypoxia Induces Genomic DNA Demethylation through the Activation of HIF-1α and Transcriptional Upregulation of MAT2A in Hepatoma Cells
    Quanyan Liu, Li Liu, Yuhong Zhao, Jin Zhang, Dongfeng Wang, Jiwei Chen, Yueming He, Jianguo Wu, Zhonglin Zhang and Zhisu Liu
    Mol Cancer Ther June 1 2011 10 (6) 1113-1123; DOI:10.1158/1535-7163.MCT-10-1010

Back to top
PreviousNext
Molecular Cancer Therapeutics: 10 (6)
June 2011
Volume 10, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • Overexpression of Mitotic Centromere–Associated Kinesin Stimulates Microtubule Detachment and Confers Resistance to Paclitaxel

Jump to

  • Highlights
  • Therapeutic Discovery
  • Preclinical Development
  • Molecular Medicine in Practice
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement